Literature DB >> 46761

Cultivation of leukemic human bone marrow cells in diffusion chambers implanted into normal and irradiated mice.

L Fauerholdt, N Jacobsen.   

Abstract

In order to elucidate the question of whether the maturation defect in vivo in acute leukemia is due to environmental or cellular factors, we have cultured human leukemic cells in a nonleukemic milieu, i.e., diffusion chambers implanted into the abdominal cavity of normal and irradiated mice. For each harvest, the cell count was measured and differential counts and the number of peroxidase-positive cells determined. The cell number decreased with time, without significant difference between culture in irradiated (500 rads) and normal mice. The blast cells succeeded only in developing distorted promyelocytes and myelocytes. There was a general pattern of increase in the number of peroxidase-positive cells. The study supports the concept that acute myeloid leukemia (AML) is a disturbance of cellular maturation due to cellular rather than environmental defects.

Entities:  

Mesh:

Year:  1975        PMID: 46761

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  4 in total

1.  The in vivo diffusion chamber technique for bone marrow or blood cell culture.

Authors:  R Willemze; R I Walker
Journal:  Blut       Date:  1981-02

2.  Growth and differentiation patterns of human acute non lymphoid leukemia in diffusion chambers before and after treatment.

Authors:  T Izzi; A Fontebuoni; G Lucarelli
Journal:  Blut       Date:  1981-07

3.  Analysis of an in vivo model to study the interaction of host factors with Candida albicans.

Authors:  A H Poor; J E Cutler
Journal:  Infect Immun       Date:  1981-03       Impact factor: 3.441

4.  Patterns of maturation in short-term culture of human acute myeloid leukaemic cells.

Authors:  G Palú; R Powles; P Selby; B M Summersgill; P Alexander
Journal:  Br J Cancer       Date:  1979-11       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.